This category includes myeloid neoplasms with preceding cytopenias and platelet disorders (e.g., inherited variants in GATA2 (GATA-binding protein 2), RUNX1 (runt-related transcription factor 1), and ETV6 (ETS Variant Transcription Factor 6)), myeloid neoplasms lacking other preexisting dysfunctions (e.g., inherited variants in CEBPA (CCAAT enhancer binding protein alpha) and DDX41 (DEAD-Box Helicase 41)), and myeloid neoplasms in the setting of bone marrow failure syndromes (e.g., Fanconi anemia) (Table 1). Here, DDX41 is linked to blood platelet disease.